SK Bioscience Launches First-in-Class Universal Coronavirus Vaccine Trial, Targeting Entire Sarbecovirus Family
核心洞察
SK bioscience (搜索) has initiated the first global Phase 1/2 clinical trial for GBP511, a universal vaccine candidate targeting the sarbecovirus (搜索) family, marking the first such vaccine to enter clinical development worldwide.
The trial will enroll approximately 368 adults in Australia to evaluate safety, tolerability, and cross-reactive immune responses against multiple coronaviruses including SARS-CoV-2 (搜索) and potential future pandemic strains.
GBP511 leverages SK bioscience (搜索)'s proven SKYCovione platform combined with nanoparticle technology, positioning the company to address the global need for broadly protective coronavirus (搜索) vaccines identified by CEPI.
SK bioscience (搜索) has launched the world's first Phase 1/2 clinical trial for a universal coronavirus (搜索) vaccine, marking a significant milestone in pandemic preparedness efforts. The South Korean biotech company announced the initiation of global trials for GBP511, a vaccine candidate designed to provide broad protection against the entire sarbecovirus (搜索) family, which includes SARS-CoV-2 (搜索) and potential future pandemic coronaviruses.
First Universal Coronavirus Vaccine to Enter Clinical Development
The international Phase 1/2 trial represents a breakthrough in vaccine development, as SK bioscience (搜索) becomes the first company globally to advance a universal coronavirus (搜索) vaccine into clinical testing. While multiple companies and research institutions have initiated efforts to develop universal coronavirus vaccines, most programs remain at an early research stage, making SK bioscience's clinical entry particularly significant.
The trial will be conducted in approximately 368 adults aged 18 years and older in Australia. In Phase 1, participants will receive two doses administered 28 days apart across low-, medium-, and high-dose cohorts, with or without an adjuvant. The study will evaluate safety, tolerability, and immunogenicity, including comparisons with Comirnaty as a comparator vaccine.
Advanced Platform Technology
GBP511 incorporates the core technology of SKYCovione, which became the only domestically developed COVID-19 (搜索) vaccine in Korea to achieve commercialization in 2022. The vaccine combines SK bioscience (搜索)'s recombinant protein technology with self-assembling nanoparticle design technology developed by the Institute for Protein Design (搜索) at the University of Washington School of Medicine (搜索).
SKYCovione previously demonstrated robust immunogenicity and a favorable safety profile through global clinical trials, providing the foundation for regulatory approval by several authorities. Building on this proven platform, GBP511 aims to induce broad immune responses across the entire sarbecovirus (搜索) family, including not only currently circulating variants but also potential future novel coronaviruses and SARS (搜索)-like coronaviruses found in animals that could potentially spill over to humans.
Strategic Importance for Pandemic Preparedness
The Coalition for Epidemic Preparedness Innovations (CEPI) has designated the SARS (搜索)-coronavirus (搜索) family as a "prototype pathogen," noting the high likelihood that future pandemics may repeatedly arise from the same viral family. CEPI has consistently emphasized the limitations of variant- or pathogen-specific approaches and highlighted the need for universal coronavirus vaccines capable of providing broad protection regardless of the emergence of novel viruses.
Dr. Richard Hatchett, CEO of CEPI, emphasized the significance of the development: "COVID 19 exposed the devastating price of confronting a deadly new virus without a vaccine. Broadly protective coronavirus (搜索) vaccines have the power to change that story. While we cannot predict when or where the next coronavirus threat will emerge, we can prepare. By investing now in all in one vaccines, CEPI and its partners are strengthening global defences—and South Korea is playing a pivotal role in that effort."
Market Implications and Future Growth
The COVID-19 (搜索) vaccine market is expected to transition from short-term outbreak-driven demand to sustained mid- to long-term growth. According to global market research firm Coherent Market Insights (搜索), the global COVID-19 vaccine market is estimated at approximately $50.6 billion in 2025 and is projected to grow at a compound annual growth rate of 7.4% from 2025 to 2032, reaching approximately $83.4 billion by 2032. Next-generation technologies, such as universal vaccines, are expected to generate new sources of market demand.
Major international journals, including Nature Reviews Immunology and The Lancet Microbe, have reported that universal sarbecovirus (搜索) vaccines capable of delivering both broad cross-neutralizing activity and durable immune protection could become a cornerstone of future pandemic preparedness strategies.
Company's Broader Pipeline Strategy
Jaeyong Ahn, CEO of SK bioscience (搜索), stated: "Developing a universal sarbecovirus (搜索) vaccine is a critical challenge that must be addressed to prepare for the next pandemic. With the initiation of the GBP511 clinical trial, we will accelerate the development of universal vaccines and leverage our proactive infectious disease preparedness capabilities to emerge as a global leader in the vaccine market."
SK bioscience (搜索) continues to advance a range of infectious disease pipelines, including a 21-valent pneumococcal conjugate vaccine and an avian influenza vaccine. The company plans to progressively expand its vaccine portfolio to strengthen mid- to long-term preparedness for future infectious disease threats.
The Phase 2 portion of the trial will assess immunogenicity and safety in adult and elderly populations, again comparing the investigational vaccine with Comirnaty. Importantly, the study will evaluate cross-reactive immune responses across the sarbecovirus (搜索) family, including SARS-CoV-2 (搜索), to assess the vaccine's potential as a universal coronavirus (搜索) vaccine.